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SIR, Metastatic Crohn’s disease is a rare dermatological
manifestation of Crohn’s disease in which there is prom-
inent granulomatous inflammation involving a skin area
that can be distant from the affected gastrointestinal tract.1
The cutaneous lesions (papules that may enlarge, ulcerate
and ⁄ or drain pus) can occur at various locations, although
they are most frequent in the perineal region, particularly
in patients with fistulizing perianal disease or previous
proctectomy.2
In contrast to other cutaneous manifestations of Crohn’s
disease, such as erythema nodosum or pyoderma gangren-
osum, metastatic Crohn’s disease usually has an unsatisfac-
tory response to medical and ⁄ or surgical therapy. A complete
healing of the lesions is rarely obtained by medical treatment,
although some partial benefit has been reported following
treatment with azathioprine,3 steroids,4 mycophenolate mo-
fetil,5 surgery and hyperbaric oxygen therapy.6
Infliximab, an antitumour necrosis factor (TNF)-a chimeric
monoclonal antibody, has been used successfully in fistulizing
perianal Crohn’s disease,7 and its potential efficacy in the
treatment of cutaneous metastatic complications of Crohn’s
disease has recently been suggested.2,8,9 We report a patient
with metastatic Crohn’s disease that was treated successfully
with infliximab.
A 31-year-old woman was initially diagnosed as having
ulcerative colitis in 1984, when she underwent a subtotal
colectomy with ileorectal anastomosis because of a toxic
megacolon. In 1986 she developed a perianal fistula and a
small perianal ulcer which gradually enlarged. Rectoscopy
and rectal biopsies revealed a morphological picture of
Crohn’s disease. In 1987 she underwent fistulectomy that
resolved the fistula but not the perianal ulceration. For about
10 years she had no intestinal or fistulous manifestation of
disease but the skin lesion persisted.
In 2002 the patient presented with a 12-cm cutaneous
ulcer located in the perianal area and extending to the gluteal
fold (Fig. 1a). No perineal fistula or mucosal alterations were
found on rectoscopy. Transrectal sonography and pelvic
magnetic resonance imaging excluded a perianal fistulizing
complication. The lesion was unresponsive to several medical
therapies (oral mesalamine; topical and systemic steroids; a
course of therapy with azathioprine for about 1 year;
metronidazole plus ciprofloxacin for 3 months). There was
local pain and bleeding, but no intestinal symptoms were
present. A biopsy of the skin ulcer revealed a noncaseating
granulomatous inflammation and the diagnosis of metastatic
Crohn’s disease was made. We proposed a course of inflix-
imab at the dosing schedule used for fistulizing Crohn’s
disease (5 mg kg)1 intravenously at 0, 2 and 6 weeks).7 Two
weeks after the third infusion of infliximab, the perianal ulcer
was completely healed (Fig. 1b) and no side-effects were
observed. There was a recurrence of the ulcer 4 months later.
A further dose of infliximab was given, initially with clinical
benefit. However, at the time of the second administration,
the patient experienced a severe immediate adverse reaction
(laryngospasm, hypotension and cutaneous rash). The
adverse reaction was effectively treated with intravenous
betamethasone 4 mg and the treatment with infliximab was
discontinued.
Figure 1. (a) The gluteal fold lesion before the first infusion of inf-
liximab. (b) Appearance of the lesion 2 weeks after the third infusion
of infliximab. Complete healing is evident.
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Metastatic Crohn’s disease, although a rare complication
of Crohn’s disease, represents a difficult problem for the
clinician because of unsatisfactory response to conventional
therapy. This condition significantly affects the patient’s
quality of life, thus justifying the search for alternative
treatments. Forty-five cases of variously localized metastatic
Crohn’s disease are reported in the literature. The thera-
peutic approach is well documented in 39 of these 45
cases.10 An improvement of metastatic lesions was
obtained in 15 of 18 patients treated with systemic or
topical steroids,3,4 in two of four patients treated with
azathioprine,3 in two patients treated with metronidazole,
in one patient treated with mycophenolate mofetil,5 in two
patients who had undergone hyperbaric oxygen therapy,6
in four of five patients treated surgically and in four
patients treated with infliximab infusion.2,8,9 Our case
represents the fifth report of metastatic Crohn’s disease
effectively treated with anti-TNF antibodies that has been
reported in the literature. In contrast to the two cases
described by van Dullemen et al.,2 the case described by
Miller et al.8 and the paediatric case described by Escher
et al.9, in which anti-TNF induced only a partial healing of
the lesions, in our patient the treatment brought about
complete resolution of the metastatic disease. Furthermore,
a re-treatment upon recurrence appeared to be effective,
even though the therapy was not completed due to an
adverse reaction.
Our experience confirms that infliximab is an effective and
well-tolerated option for the treatment of therapy-resistant
metastatic Crohn’s disease, indirectly suggesting the TNF-a-
dependent nature of this cutaneous complication.
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Eczema-like lesions and disruption of therapy
in patients treated with interferon-alfa and ribavirin
for chronic hepatitis C: the value of an
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SIR, I would urge upon you in your own practice, to care more
particularly for the individual patient than for the special features
of the disease (William Osler).
We read with interest the controversy in the BJD1,2
regarding the premature withdrawal from therapy with
interferon-alfa and ribavirin in patients treated for chronic
hepatitis C (CHC), due to eczema-like lesions. In the study of
Dereure et al.1 this combined treatment had to be interrupted
in half of their patients presenting with diffuse eczema-like
lesions (10 of 20). On the other hand, Kerl et al.2 followed 52
patients undergoing combination treatment with peginterfer-
on alfa and ribavirin, of whom 12 (23%) developed eczema-
like lesions but, in contrast to Dereure et al. none had to
interrupt the antiviral treatment, as the lesions were well
controlled with topical corticosteroids and emollients.
We consider it to be of interest to add our experience to this
controversy.3 We evaluated 210 patients with CHC under-
going a 1-year treatment with recombinant interferon-alfa 2b
and ribavirin, between June 1998 and September 2000. Not
taking into account local reactions to injections, we observed
de novo skin lesions in 27 patients (13%). Among patients
with skin lesions, 16 patients (59%) presented eczema-like
lesions, mostly localized on the legs, arms or trunk. Only two
of them had generalized eczematous lesions with very severe
pruritus. We also observed disseminated prurigo-like lesions
(four patients, 2%); lichenoid eruptions (two patients, 1%);
seborrhoeic dermatitis (two patients, 1%); maculopapular
exanthema (two patients, 1%) and herpes zoster (one patient,
0Æ5%).
We treated those patients presenting with diffuse, eczema-
like lesions and pruritus with oral hydroxyzine, moderately
potent topical steroids and emollients. Most of them were well
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